AKT1 and cancer: Phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin (mTOR) signaling pathway, which controls cell proliferation, is abnormally activated in several cancers and also in MM patients [37]; therefore, a drug that inhibits this pathway might be effective in the treatment of MM.